Ultram

Active Pharmaceutical Ingredient Of Ultram The Tenuate drug is generally prescribed for the suppression of appetite, and is used in conjunction with an overall diet plan and an exercise program to reduce weight and manage obesity. A brief on the directions of Tenuate drug reveals that this medication must be taken in an empty stomach, and preferably one-half hour prior to having breakfast. Due to the feelings of drowsiness and sleeplessness, it is generally advised that the drug should not be taken during later part of the day. Specific instructions from the consulting physician is the best strategy, and one should not take more than the prescribed dosage, and for a period specifically directed by the consulting physician. Some of the side effects associated with the use of Tenuate drug include dry mouth, sleeplessness, irritability, stomach upset or constipation in the first few days after commencing Tenuate. It is generally advised that if either of these symptoms persist, or become bothersome, the consulting physician or the area doctor must be immediately notified. As to the brief on some of the precautions on the use of Tenuate drug for managing obesity and reducing weight, it is generally advised that prior conditions and ailments of high blood pressure, heart diseases, overactive thyroid, glaucoma, diabetes or emotional problems. Furthermore, women who are pregnant, and those breast-feeding their infants are also advised against the use of Tenuate due to its severe side effects. The use of Tenuate is also not recommended for those using alcohol or is know abusers of drugs. Tenuate is also not recommended for children. As a note of precaution, it is suggested that since Tenuate is an appetite suppressant and is not a substitute for proper diet, the best results are obtained through a proper diet plan and an exercise program, yet without the assistance or combination of other drugs.

Tramadol HCl (Ultram, Ortho-McNeil), is a centrally acting, synthetic, binary analgesic. The drug was approved by the FDA March 7, 1995, and is indicated for the management of moderate to moderately severe pain. The drug has been used in more than 39 million patients in 70 countries since 1977. Tile FDA has not classified tramadol as a controlled substance. Tramadol-associated adverse effects have been reported. Adverse effects occurred in approximately 15% of patients who received up to 400 mg/day. The adverse reactions were similar to those reported with opioids. The most prominent adverse effects involve the central nervous system and the gastrointestinal tract. Common adverse effects reported in the trials reviewed in this Focus include nausea, vomiting, dizziness, somnolence, drowsiness, constipation, restlessness, sweating, headache, and palpitations. Tramadol's potential for chemical psychological dependency is apparent low. A review of the foreign clinical experience revealed only 152 cases in 39 million patients.The explanation for this low risk is due to the delayed mu opioids effect of the active M1 metabolite. Tramadol should be used with extreme caution in patients receiving monoamine oxidase inhibitors. Caution should also be exercised and a reduced dose given when tramadol is administered with alcohol, sedative hypnotics, opioids analgesics, anesthetic agents, or other agents that act upon the central nervous system (CNS). Likewise, CNS-related adverse effects may arise if over-the-counter cold, sleep, and analgesic medications are taken with tramadol. Respiratory depression may occur if the recommended dosage is consistently exceeded or if another centrally acting depressant drug (eg, alcohol, anesthesia) is given concurrently.